Kymera Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 86.48, 41.86, 39.68, 61.16, 185.9 ], "ebit_estimate": [ -392.83, -478.03, -519.96, -546.16, -458.9 ], "ebitda_estimate": [ -377.13, -427.24, -429.36, null, null ], "net_income_estimate": [ -339.23, -433.3, -477.73, -499.07, -395.38 ], "per_share_eps_estimate": [ -3.52, -4.36, -4.71, -4.68, -3.65 ], "eps_nri_estimate": [ -3.52, -4.29, -4.61, -4.68, -3.65 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 13.68, 10.51, 7.12, null, null ], "pretax_income_estimate": [ -338.72, -426.93, -479.41, -513.49, -439.7 ], "operating_cash_flow_per_share_estimate": [ -3.27, -3.81, -3.61, -3.23, -3.26 ], "roa_estimate": [ -22.35, -31.25, -62.2, -97, -170.3 ], "roe_estimate": [ -23.43, -28.63, -45.48, -122.2, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 98.67 ], "operating_cash_flow_estimate": [ -318.69, -372, -351.78, -315.04, -317.96 ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -9.07, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -9.9, "future_eps_nri_estimate_growth": -9.07, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -14.9, "future_ebitda_estimate_growth": -8.49, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -16.52, "future_pretax_income_estimate_growth": -16.49, "future_book_value_per_share_estimate_growth": -27.92, "future_roa_estimate_growth": -39.57, "future_roe_estimate_growth": -20.96, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -10.06 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 29.38, 8.24, 10.73, 11.25, 12.5, 12.5, 12.5 ], "ebit_estimate": [ -89.61, -111.09, -110.84, -111.98, -116.2, -118.93, -123.05 ], "ebitda_estimate": [ -103.41, -97.85, -110.41, null, null, null, null ], "net_income_estimate": [ -75.52, -98.96, -99.14, -100.88, -105.54, -107.96, -112.77 ], "per_share_eps_estimate": [ -0.75, -1.03, -1.02, -1.02, -1.06, -1.04, -1.07 ], "eps_nri_estimate": [ -0.73, -1.02, -1.01, -1.02, -1.04, -1.02, -1.05 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -77.89, -96.98, -98.38, -97.73, -102.01, -103.14, -107.62 ], "operating_cash_flow_per_share_estimate": [ -0.78, -0.79, -1.01, null, null, null, null ], "roa_estimate": [ -3.7, -7, -7.6, null, null, null, null ], "roe_estimate": [ -4.1, -7.7, -8.3, null, null, null, null ], "gross_margin_estimate": [ 100, 100, 100, 100, 100, 100, 100 ], "operating_cash_flow_estimate": [ -75.59, -76.56, -98.02, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -9.07, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -9.9, "future_eps_nri_estimate_growth": -9.07, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -14.9, "future_ebitda_estimate_growth": -8.49, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -16.52, "future_pretax_income_estimate_growth": -16.49, "future_book_value_per_share_estimate_growth": -27.92, "future_roa_estimate_growth": -39.57, "future_roe_estimate_growth": -20.96, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": -10.06 }